Cancer regression in patients after transfer of genetically engineered lymphocytes

Science

Volumn 314, Issue 5796, 2006, Pages 126-129

  Morgan, Richard A ^a   Dudley, Mark E ^a   Wunderlich, John R ^a   Hughes, Marybeth S ^a   Yang, James C ^a   Sherry, Richard M ^a   Royal, Richard E ^a   Topalían, Suzanne L ^a   Kammula, Udai S ^a   Restifo, Nicholas P ^a   Zheng, Zhili ^a   Nahvi, Azam ^a   De Vries, Christiaan R ^a   Rogers Freezer, Linda J ^a   Mavroukakis, Sharon A ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOLOGOUS LYMPHOCYTES; CANCER REGRESSION; LYMPHOCYTES; METASTATIC MELANOMA;

BLOOD; CELLS; DRUG INFUSION; PATIENT TREATMENT; TUMORS; VIRUSES;

GENETIC ENGINEERING;

CD4 ANTIGEN; CD8 ANTIGEN; HLA A ANTIGEN; INTERLEUKIN 2; MELAN A; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

BLOOD; CANCER; DISEASE TREATMENT; GENETIC ENGINEERING; TUMOR;

ADOPTIVE TRANSFER; ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; GENETIC ENGINEERING; HUMAN; HUMAN CELL; LIVER METASTASIS; LYMPHOCYTE; MALE; MELANOMA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE;

ADOPTIVE TRANSFER; ADULT; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; ELECTROPORATION; FEMALE; GENE THERAPY; GENETIC ENGINEERING; HLA-A ANTIGENS; HUMANS; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 33749624177     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1129003     Document Type: Article

References (21)

1. S. A. Rosenberg, Immunity 10, 281 (1999).
2. J. N. Blattman, P. D. Greenberg, Science 305, 200 (2004).
3. S. A. Rosenberg, P. Spiess, R. Lafreniere, Science 233, 1318 (1986).
4. M. E. Dudley et al., J. Clin. Oncol. 23, 2346 (2005).
5. M. E. Dudley et al., Science 298, 850 (2002).
6. M. Krogsgaard, M. M. Davis, Nat. Immunol. 6, 239 (2005).
7. T. N. Schumacher, Nat. Rev. Immunol. 2, 512 (2002).
8. M. Sadelain, I. Riviere, R. Brentjens, Nat. Rev. Cancer 3, 35 (2003).
9. Y. Zhao et al., J. Immunol. 174, 4415 (2005).
10. R. A. Morgan et al., J. Immunol. 171, 3287 (2003).
11. M. S. Hughes et al., Hum. Gene Ther. 16, 457 (2005).
12. C. J. Cohen et al., J. Immunol. 175, 5799 (2005).
13. Materials and methods are available as supporting material on Science Online.
14. S. R. Riddell, P. D. Greenberg, J. Immunol. Methods 128, 189 (1990).
15. D. B. Kohn et al., Nat. Med. 4, 775 (1998).
16. P. Therasse et al., J. Natl. Cancer Inst. 92, 205 (2000).
17. C. J. Cohen et al., Cancer Res. 66, 8878 (2006).
18. L. Yang, D. Baltimore, Proc. Natl. Acad. Sci. U.S.A. 102, 4518 (2005).
19. L. Gattinoni et al., J. Exp. Med. 202, 907 (2005).
20. W. W. Overarijk et al., J. Exp. Med. 198, 569 (2003).
21. The authors acknowledge the expert help in the care of these patients provided by the Surgery Branch Immunotherapy Fellows; J. Gea-Banacloche for valuable advice concerning the management of infectious complications; the nurses on the 3NW and Surgical intensive care unit wards in the Clinical Center; and NIH, as well as A. Mixon and S. Farid for fluorescence-activated cell sorting analysis. We also thank K. Cornetta and the National Gene Vector Laboratory for production of the clinical-grade retroviral vector. This work was supported by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, NIH.